Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Interest & Investment Income: 2023-2025

Historic Interest & Investment Income for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to $6.7 million.

  • NewAmsterdam Pharma Co N.V's Interest & Investment Income rose 51.09% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.6 million, marking a year-over-year increase of 69.97%. This contributed to the annual value of $16.9 million for FY2024, which is 49.61% up from last year.
  • As of Q3 2025, NewAmsterdam Pharma Co N.V's Interest & Investment Income stood at $6.7 million, which was down 4.85% from $7.1 million recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's 5-year Interest & Investment Income high stood at $7.4 million for Q1 2025, and its period low was $943,000 during Q1 2023.
  • Moreover, its 3-year median value for Interest & Investment Income was $4.5 million (2024), whereas its average is $4.5 million.
  • Data for NewAmsterdam Pharma Co N.V's Interest & Investment Income shows a peak YoY soared of 226.94% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows NewAmsterdam Pharma Co N.V's Interest & Investment Income stood at $2.7 million in 2023, then spiked by 68.10% to $4.5 million in 2024, then skyrocketed by 51.09% to $6.7 million in 2025.
  • Its Interest & Investment Income stands at $6.7 million for Q3 2025, versus $7.1 million for Q2 2025 and $7.4 million for Q1 2025.